There are currently 491 clinical trials in Lexington, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Kentucky, University of Kentucky/Markey Cancer Center, Saint Joseph Hospital East and Baptist Health Lexington. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Thoracic-Lumbar Arthrodesis- Implanet Jazz
NCT05366140
Recruiting
Establish a data repository of patients who have undergone single, two-, or three-level lumbar instrumented arthrodesis procedures supplemented by the Implanet Jazz System.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
10/08/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Spondylolisthesis, Spinal Stenosis, Degenerative Disease
Register for Updates
Spinal Cord Injury Neuroprotection With Glyburide
NCT05426681
Recruiting
To assess the safety and efficacy of using oral Glyburide (Diabeta) as a neuroprotective agent in patients with acute cervical or thoracic traumatic spinal cord injury.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/08/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Acute Spinal Cord Injury
Register for Updates
Flat Dose Vs. Weight-based IP Chemotherapy for CRS/HIPEC
NCT04779554
Recruiting
Peritoneal carcinomatosis from advanced gastro-intestinal malignancy has historically been associated with poor overall survival (≤ 12 months) with few treatment options. Cytoreductive surgery (CRS), which involves removal of all macroscopic tumor nodules, combined with direct administration of heated intra-peritoneal (IP) chemotherapy (HIPEC) to the affected peritoneal surfaces, has been shown to be an effective treatment option that extends overall survival among certain cases of peritoneal ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Peritoneal Carcinomatosis
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/04/2024
Locations: Local Institution - 017-965, Lexington, Kentucky
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT04202341
Recruiting
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Clinical Trial Site, Lexington, Kentucky
Conditions: Generalized Myasthenia Gravis
Register for Updates
Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections
NCT04677114
Recruiting
This study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections. The investigators hypothesize that outpatient antibiotic treatment coupled with comprehensive treatment for opioid use disorder will demonstrate a safe and effective way to manage patients. Results could improve the current protocols for the treatment of individuals with opioid use disorder and severe infections.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/23/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Drug Use, Opioid-use Disorder
Register for Updates
ArtemiCoffee in Patients With Rising PSA
NCT05478239
Recruiting
Until now, clinicians have been challenged to improve the treatment of biochemically recurrent (BCR) prostate cancer in which prostatic specific antigen (PSA) rises without radiological or clinical progression years after localized treatment (radical prostatectomy or radiation therapy) with or without hormonal treatment. Approximately 50-90% of men with high-risk prostate cancer will experience a BCR. Artesunate has demonstrated anti-tumor activity in both in vivo and in vitro cell lines. It is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/22/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Prostate Cancer
Register for Updates
Hepatitis C Treatment in Probation and Parole Office
NCT05413785
Recruiting
This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P\&P office) setting and compare the results with a historic control with referral to care. Research participants will be followed in the P\&P office when they report to their officer during regularly scheduled appointments. Participants will receive treatment without having to travel to a specialist's... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/19/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Hepatitis C, HCV
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
Neuroblastoma Maintenance Therapy Trial
NCT02679144
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
09/18/2024
Locations: Kentucky Children's Hospital, Lexington, Kentucky
Conditions: Neuroblastoma
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk... Read More
Gender:
FEMALE
Ages:
Between 35 years and 50 years
Trial Updated:
09/17/2024
Locations: Baptist Health Lexington, Lexington, Kentucky
Conditions: Ovarian Carcinoma
Register for Updates
Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment
NCT04634071
Recruiting
Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: University Of Kentucky, Markey Cancer Center, Lexington, Kentucky
Conditions: Smoking Cessation, Cancer, Treatment-Related
Register for Updates